Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like Phenotype

8 Aug 2019

Abstract excerpt

Abstract Pancreatic cancer remains an incurable condition. Its progression is driven, in part, by subsets of cancer cells that evade the cytotoxic effects of conventional chemotherapies. These cells are often low-cycling, multidrug resistant, and adopt a stem cell–like phenotype consistent with the concept of cancer stem cells (CSC). To identify drugs impacting on tumor-promoting CSCs, we performed a differential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31395684
DOI: 10.1158/1535-7163.mct-18-1011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Target Deconvolution of a Multikinase Inhibitor with Antimetastatic Properties Identifies TAOK3 as a Key Contributor to a Cancer Stem Cell–Like PhenotypePMID 31395684Read ↗

Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivoSemantic proximity Read ↗

Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic CancerSemantic proximity Read ↗

Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalenceSemantic proximity Read ↗

Cancer Therapies: Cellular and Molecular MechanismsSemantic proximity Read ↗

Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem CellsSemantic proximity Read ↗

Dualistic effects of PRKAR1A as A Potential Anticancer Target in Cancer Cells and Cancer-Derived Stem CellsSemantic proximity Read ↗

Kinase-targeted cancer therapies: progress, challenges and future directionsSemantic proximity Read ↗

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistanceSemantic proximity Read ↗

Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancersSemantic proximity Read ↗

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read ↗

A 1536-Well Quantitative High-Throughput Screen to Identify Compounds Targeting Cancer Stem CellsSemantic proximity Read ↗

Evolution of PIKK family kinase inhibitors A new age cancer therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.